Jump to content
RemedySpot.com

It All Began With Interferon / HCV Treatment

Rate this topic


Recommended Posts

Guest guest
Posted

It All Began With Interferon / HCV Treatment

Interferon is a protein produced by animals in response to viral infections. It is a defensive mechanism by the body to prevent multiplication of the virus. The action of interferon was first demonstrated in 1957 by British virologist Alick Isaacs (1921-1967) and his Swiss colleague Lindenmann. Isaacs was born in Glasgow, Scotland, in 1921, to a Russian Jewish family. He studied medicine at Glasgow University but found he preferred research to the actual practice of medicine.Viral Interference

Early in his studies of influenza (flu) at the World Influenza Centre at the National Institute for Medical Research in England, Isaacs became interested in the viral interference phenomenon, first described in 1935. It was observed that an RNA virus in a cell inhibits (restrains) the growth of any other viruses in that cell. While trying to discover the mechanism by which this occurs, Isaacs found that the interference seemed to be caused by something inside the cell.While working with the visiting Swiss scientist Lindenmann in 1957, Isaacs found that chick embryos (developing eggs) injected with influenza virus released very small amounts of a protein that destroyed the virus. The protein also inhibited the growth of any other viruses in the embryos. Isaacs and Lindenmann named the interfering protein interferon.It is now known that interferon is produced within hours of a viral invasion and that most living

things, including plants, can make the protective protein. Interferon was initially seen as the cell's first line of defense against viral infections, and its discovery was expected to pave the way for successful treatment of viral diseases. Researchers soon found, however, that interferon is "species-specific." (Only human interferon, for example, will work in human beings.) The body also produces interferon in only small amounts, making it extremely expensive to obtain. These difficulties caused interferon research to inch forward at only a slow pace.New Interest

The late 1960s saw renewed interest in interferon when Ion Gresser (1928-), an American researcher in Paris, discovered that the protein stopped or slowed the growth of tumors in mice and also stimulated the production of tumor-killing lymphocytes (white blood cells). Gresser and Finnish virologist Karl Cantell both developed a way to make interferon in useful amounts from human blood cells. Monoclonal antibodies, first produced in 1975, made large-scale purification of interferon possible. The mid-1980s saw the advent of genetically-engineered interferon, the first example of which was produced from bacteria by Swiss scientist Weissmann in 1980.Research of interferon's ability to kill cancer cells has yielded only mixed results. It has been successfully used, however, against leukemia and osteogenic sarcoma (a bone cancer). Interferon shows varied promise in treating one type of multiple sclerosis, melanoma, renal

cell cancer, and a few AIDS-related Kaposi's sarcomas. Interferon is also used to treat viral diseases like rabies, hepatitis, and herpes infections.

Interferon (in one form or another) has been used to treat hepatitis C since 1991 and ribavirin has been used in combination with an interferon product since1998.

We are now on the brink of a new treatment regime that will include direct HCV antivirals (protease and polymerase inhibitors). These new medications, when combined with pegylated interferon and ribavirin, are expected to increase HCV response rates.

The new treatment regimes are expected to be approved in 2011-2012, and pegylated interferon and ribavirin is expected to be part of HCV therapy for another10 years or maybe even longer. Therapies that do not include interferon and/or ribavirin are in early stages of development and do hold much promise; but right now there are too many unknowns to make any type of intelligent guess. Given that we will have to livewith interferon and ribavirin for the foreseeable future, this fact sheet

will discuss the current combination of interferon and ribavirin with regard

to what we know and don’t know about these medications.There are two types of Interferons that are naturally produced by the body. Type II interferon is mainly involved with controlling the immune functions of the body.

There is only one form of Type II interferon – gamma interferon.

Type I interferon is known as alpha or beta and is made up of proteins produced by the body in response to a viral infection. For instance, when someone becomes infected with the fluvirus the immune system immediately produces and releases various types of interferon to protect cells from the invading virus.

The symptoms people experience from the flu, suchas muscle pain, fever and headaches, are due to the body’s natural production of interferon.In more detail, interferon works by binding to cell surface receptors and triggering the production of intracellular second messengers, including 2’5’ oligo-adenylate synthetase,protein kinases, cell surface proteins, and nuclear proteins.

Interferon also works in other ways by increasing the body’s immuneresponse against viruses and infected cells:

• Antiviral action – Interferon helps to prevent the entryof a virus into a cell, which limits the replication of newviruses and the amount of new cells that the virus infects.Within the liver cell interferon inhibits the replication ofviruses by preventing the virus from uncoating and byinterfering with viral protein synthesis.

• Immunomodulatory effect – Interferon stimulatesthe production of cytokines (chemical messengers) thatactivate macrophages, natural killer (NK) cells, and cytotoxicT-lymphocytes (CTLs, or killer T-cells) which thensurround and kill the infected cell and the virus withinthe cell.

• Antitumor effects – Interferon reduces the production ofboth normal and malignant (cancerous) cells and inhibitsoncogene expression. Interferon also enhances directT-cell-mediated cytotoxicity against tumor cells. This killscancer and tumor cells.

• Enhanced cell surface expression of MHC – Interferonenhances the expression of class 1 majorhistocompatibility (MHC) antigens on the surface ofinfected cells. Expression of these proteins on the cellsurface allows virus-infected cells to be targeted anddestroyed by CTLs.

Sometimes the body does not make enough natural interferon to effectively

fight an infection – the addition of genetically re-engineered interferon helps the

body to fight off a viral infection such as hepatitis C.Standard

Interferon Standard interferons (also called conventional interferon) are administered

by subcutaneous injection (right underneath the skin) three times a week.

Standard interferon’s half life (the time required by the body to metabolizeor inactivate half the amount of the substance) is two to five hours.

Because of standard interferon’s short half-life it is unable to constantly

suppress the hepatitis C virus. Standard interferon is a premixed solution.

The first standard interferon, Intron A brand, was approved in 1991.The most common FDA approved standard interferons used to treat hepatitis C

include Genentech’s Roferon-A, Merck’s Intron A, and

Three Rivers Pharmaceutical’s Infergen.

Pegylated InterferonPegylated interferon is a long-acting formulation of interferonthat can be injected less often – once a week. Pegylation isa process in which polyethylene glycol (the PEG molecule) is attached to a protein. This creates a shield around the interferonwhich helps to protect it and also delays the breakdown and clearance of interferon from the body. Since the PEG module allows interferon to stay in the body longer there isgreater suppression of the hepatitis C virus.

There are currently two FDA approved pegylated interferons – Merck’s Peg-Intron was approved in August 2001; and Roche’s Pegasys was approved in October 2002.

Ribavirin Ribavirin (Rebetol, produced by Merck; Copegus, produced by Genentech; or Ribasphere, produced by Three Rivers Pharmaceuticals) is a nucleoside analog (also called a nucleosidereverse transcriptase inhibitor, or NRTI) antiviral drug. It is taken orally (by mouth) twice a day. The exact way ribavirin works is unknown. However, it is believed that when ribavirinenters a cell it is phosphorylated; it then acts as an inhibitor of inosine 5’-monophosphate dehydrogenase (IMPDH).IMPDH inhibitors such as ribavirin reduce the intracellular synthesis and storage of guanine, a nucleotide “building block†necessary for DNA and RNA production, thus inhibitingviral replication. IMPDH inhibitors also interfere with the reproduction of rapidly proliferating cells and cells with a high rate of protein turnover; because of this, IMPDH inhibitorscan cause side

effects such as nausea and immunosuppression.

Treatment with ribavirin monotherapy has little effect on HCV RNA levels, but is associatedwith a decline in serum ALT. This suggests that ribavirin may not be acting asan antiviral agent, but rather as a modulator of immune system function. Ribavirinmonotherapy for HCV is ineffective, and the drug is only approved for use in combinationwith interferon.

Today’s Standard of Care:The current standard of care is the combinationof pegylated interferon plus ribavirin. Thestandard duration of treatment is 48 weeksfor genotype 1 and 24 weeks for genotypes2 and 3. Ribavirin is taken twice a day (withfood) and is dosed by body weight for indi-viduals with

HCV genotype 1 (800 to 1,400 mg a day) andin people with HCV genotype 2 and 3 it is given at a flat orfixed daily dose of 800 mg.Peg-Intron (peginterferon alpha 2b) plus ribavirinPeg-Intron is a lyophilized powder that must be reconstitutedbefore use. It is dosed by body weight.

The sustained virological response rate (SVR) for Peg-Intron

monotherapy is 14% for genotype 1 and 47% for genotypes 2 and 3.

The SVR for Peg-Intron plus ribavirin combination therapy is 41% forgenotype 1 and 75% for genotypes 2 through 6.

Pegasys (peginterferon alfa 2a) plus ribavirinPegasys comes in a ready-made solution that does not requirereconstitution. The standard dose is 180 μg for all patients.The SVR for Pegasys monotherapy is 28% for genotype 1and 56% for genotypes 2 and 3. Pegasys monotherapy isalso indicated for treatment of chronic hepatitis B and forpeople with compensated cirrhosis.

The SVR for Pegasys plus ribavirin combination therapy

is 44-51% for genotype 1 and 70-82% for genotypes 2 through 6. Pegasys plus ribavirin combination therapy is also indicated for treatinghepatitis C in people with HIV.

Newer types of interferons:Albumin, interferon brand name ZALBIN, is a long-actingtype of interferon that is fused with the blood protein albuminneeds to be injected only once every two weeks. In Phase IIIstudies it was found that ZALBIN met the primary end-pointof the study – that is, that the treatment results were foundto be non-inferior to Pegasys. Human Genome Sciencesand their co-development partner, Norvartis, have sent theclinical trial data to the FDA for consideration for marketingapproval. If approved by the FDA the most likely timeframefor release would be late 2010-2011.

There are many other types of interferon that are beingdeveloped and tested to treat hepatitis C. IL-29 (type IIIinterferon), Belerofon (an oral medication), and Locteronlook promising, but the push for HCV therapies that do notinclude interferon and/or ribavirin calls into question an aggressivepush to develop these and other interferons, at leastwith regard to a treatment for hepatitis C.http://www.hcvadvocate.org/hepatitis/factsheets_pdf/Interferon_Rib_10.pdf

New Drugs

Keep Updated: May 26 : Telaprevir or Boceprevir

..Read more: http://www.discoveriesinmedicine.com/Hu-Mor/Interferon.html#ixzz0pfcnlnVr

http://Hepatitis Cnewdrugs.blogspot.com/2010/06/it-all-began-with-interferon-hcv.html

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...